Last reviewed 2026-04-20 · How we verify

Beta-Diethylaminoethyl Nicotinate (NICAMETATE)

Phase 2 active Small molecule

Beta-Diethylaminoethyl Nicotinate (generic name: NICAMETATE) is a nicametate drug. It is currently in Phase 2 development.

Beta-Diethylaminoethyl Nicotinate works by interacting with nicotinic receptors in the body.

Beta-Diethylaminoethyl Nicotinate (NICAMETATE) is a small molecule nicametate drug with unknown target and FDA approval status. It is used to treat unknown indications. The commercial status of NICAMETATE is unclear, with unknown generic manufacturers and patent status. Key safety considerations are also unknown. Further research is needed to understand the pharmacology and clinical use of NICAMETATE.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	NICAMETATE
Drug class	nicametate
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have special locks called nicotinic receptors. Beta-Diethylaminoethyl Nicotinate is a key that fits into these locks, helping to regulate various bodily functions. This interaction can have different effects depending on the specific lock and the body's needs.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Beta-Diethylaminoethyl Nicotinate CI brief — competitive landscape report
Beta-Diethylaminoethyl Nicotinate updates RSS · CI watch RSS

Frequently asked questions about Beta-Diethylaminoethyl Nicotinate

What is Beta-Diethylaminoethyl Nicotinate?

Beta-Diethylaminoethyl Nicotinate (NICAMETATE) is a nicametate drug.

How does Beta-Diethylaminoethyl Nicotinate work?

Beta-Diethylaminoethyl Nicotinate works by interacting with nicotinic receptors in the body.

What is the generic name of Beta-Diethylaminoethyl Nicotinate?

NICAMETATE is the generic (nonproprietary) name of Beta-Diethylaminoethyl Nicotinate.

What drug class is Beta-Diethylaminoethyl Nicotinate in?

Beta-Diethylaminoethyl Nicotinate belongs to the nicametate class. See all nicametate drugs at /class/nicametate.

What development phase is Beta-Diethylaminoethyl Nicotinate in?

Beta-Diethylaminoethyl Nicotinate is in Phase 2.

Drug class: All nicametate drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing